API manufacturing facility in Telangana, India, has received an Establishment Inspection Report (EIR) from the U.S. FDA with a 'Voluntary Action Indicated' (VAI) classification. This follows a for-cause inspection conducted from August 21-29, 2025, which resulted in Form 483 with 5 observations. The FDA has determined that the issues cited in both the January 2022 warning letter and the Form 483 have been adequately addressed. The VAI classification suggests that while there are deficiencies, they are not serious enough for immediate regulatory action. This development is expected to positively impact the unit's operations. Please note that the information shared is intended solely for informational purposes and does not make any investment recommendations.